Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-04-08
2008-04-08
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C514S002600, C514S008100, C530S350000, C530S395000
Reexamination Certificate
active
07354588
ABSTRACT:
The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
REFERENCES:
patent: 4789734 (1988-12-01), Pierschbacher
patent: 5284931 (1994-02-01), Springer et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5589453 (1996-12-01), Greve
patent: 0 319 815 (1989-06-01), None
Dustin, M. L. et al., J. Immunology 137(1):245-254, “Induction by IL-1 and Interferon gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)” Jul. 1, 1986.
Paul, W.F. (ed.) Fundamental Immunology, 3rd edition, pp. 1163-1170, Raven Press, New York, 1993.
Staunton, D. E. et al., Cell 52:925-933, “Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families” Mar. 25, 1988.
Tomassini, J. Virol. 58(2): 290-295, “Isolation of a receptor protein involved in attachment of human rhinovirus” May 1986.
Smilek, D. et al., PNAS 88:9633-9637, A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce EAE, Nov. 1991.
Tomassini, J. E., Dissertation, Diss. Abs. Int. B 1987 47(7):2774. Isolation, characterization and cloning of the cellular receptor for the major group of human rhinoviruses, 1986.
Colonno et al. Virus Attachment and Entry Into Cells, Proceedings of an Conference Held in Phila. PA, Apr. 10-13, 1985. pp. 109-115, Crowell et al. (Eds.) American Society for Microbiology Washington DC 1986.
Tomassini et al. PNAS 86: 4907-494(1989).
Wiliams et al. in Weir et al. (EDS.) Handbook of Experimental Immunology, vol. 1: Immunochemistry Fourth Edition, Blackwell Scienetific Publications, Oxford 1986; pp. 22.1-22.24.
Clark et al., Human Immunology 16: 100-113, 1996.
Dustin et al., Immunology Today 9: 213-215, 1988.
Alexander, E.L.et al., “Cutaneous Manifestations of Sjögren's Syndrome,” in:Immunologic Diseases of the Skin, Jordon, R.E. (ed.) Norwalk, CT: Appleton & Lange, pp. 401-408 (1991).
Anderson, D.C. et al., “Leukocyte LFA-1, OKM1, p150, 95 deficiency syndrome: functional and biosynthetic studies of three kindreds,”Fed. Proceedings 44(10) :2671-2677 (Jul. 1985).
Anderson, D.C. et al., “Leukocyte Adhesion Deficiency: An Inherited Defect in the Mac-1, LFA-1, and p150, 95 Glycoproteins.”Ann. Rev. Med. 38:175-194 (1987).
Bashir, R. et al., “Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain,”J. Neuro-Oncol. 12:103-110 (1992).
Boyd, A.W. et al., “Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms,”Proc. Natl. Acad. Sci. USA 85:3095-3099 (May 1988).
Byers, V.S. et al., “Use of an Anti-Pan T-Lymphocyte Ricin A Chain Immunotoxin in Steroid-Resistant Acute Graft-Versus-Host Disease,”Blood 75(7):1426-1432 (Apr. 1, 1990).
Colonno, R.J. et al., “Isolation of a Monoclonal Antibody That Blocks Attachment of the Major Group of Human Rhinoviruses,”J. Virol. 57(1):7-12 (Jan. 1986).
Cooper, K.D. et al., Immunologic Features of Psoriasis,in: Immunologic Diseases of the Skin, Jordon, R.E. (ed.), Norwalk, CT: Appleton & Lange, pp. 611-619 (1991).
Cosimi, A.B. et al., “In Vivo Effects Of Monoclonal Antibody To ICAM-1 (CD54) In Nonhuman Primates With Renal Allografts,”J. Immunol. 144(12 ):4604-4612 (Jun. 15, 1990).
Cunningham, C. et al., “Antibody engineering —how to be human,”TIBTECH 10(Apr. 1992).
Dantal, J. et al., “Use of monoclonal antibodies in human transplantation,”Curr. Opin. Immunol. 3:740-747 (1991).
Davignon, D. et al., “Lymphocyte function-associated antigen 1 (LFA-1): A surface antigen distinct from Lyt-2,3 that participates in T Lymphocyte-mediated killing,”Proc. Natl. Acad. Sci. USA 784535-4539 (Jul. 1981).
Dustin, M.L. et al., “Adhesion Of T Lymphoblasts To Epidermal Keratinocytes Is Regulated By Interferon γ And Is Mediated By Intercellular Adhesion Molecule 1 (ICAM-1), ”J. Exp. Med. 167:1323-1340 (Apr. 1988).
Dustin, M.L. et al., “Induction By IL 1 And Interferon-τ: Tissue Distribution, Biochemstry, And Function Of A Natural Adherence Molecule (ICAM-1), ”J. Immunol. 137(1):245-254 (Jul. 1, 1986).
Dustin, M.L. et al., “Lymphocyte Function-associated Antigen-1 (LFA-1) Interaction with Intercellular Adhesion Molecule-1 (ICAM-1) is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells,”J. Cell Biol. 107:321-331 (Jul. 1988).
Dustin, M.L. et al., “Purified Lymphocyte Function-Associated Antigen 3 Binds To CD2 And Mediates T Lymphocyte Adhesion,”J. Exp. Med. 165:677-692 (Mar. 1987).
Dustin, M.L. et al., “Supergene families meet in the immune system,”Immunol. Today 9(7&8):213-215 (1988).
Dustin, M.L. et al., “T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1,”Nature 341:619-624 (Oct. 19, 1989).
Fischer, A. et al., “Role Of The LFA-1 Molecule In Cellular Interactions Required For Antibody Production In Humans,”J. Immunol. 136(9):3198-3203 (May 1, 1986).
Flavin, T. et al., “Monoclonal Antibodies Aganist Intercellular Adhesion Molecule 1 Prolong Cardiac Allograft Survival in Cynomoglus Monkeys,”Transplant. Proc. 23(1):533-534 (Feb. 1991).
Gibbs, “Try, Try Again: Making antibodies more useful by making them more human,”Scientific American:101-103 (Jul. 1993).
Hamann, A. et al., “Evidence For An Accessory Role Of LFA-1 In Lymphocyte-High Endothelium Interaction During Homing,”J. Immunol. 140(3):693-699 (Feb. 1, 1988).
Harlan, J.M. et al., “Leukocyte-Endothelial Interactions,”Blood 65(3):513-525 (Mar. 1985).
Harris, W.J. et al., “Therapeutic antibodies—the coming of age,”TIBTECH 11:42-44 (Feb. 1993).
Haskard, D. et al., “T Lymphocyte Adhesion To Endothelial Cells: Mechanisms Demonstrated By Anti-LFA-1 Monoclonal Antibodies,”J. Immunol. 137:2901-2906 (Nov. 1986).
Haug, C.E. et al., “A Phase I Trial Of Immunosuppression With Anti-ICAM-1 (CD54) mAb In Renal Allograft Recipients,”Transplantation 55(4):766-773 (Apr. 1993).
Hildreth, J.E.K. et al., “Involvement of a Leukocyte Adhesion Receptor (LFA-1) in HIV-Induced Syncytium Formation,”Science 244:1075-1078 (Jun. 2, 1989).
Hoffman, P.M. et al., “Neurologic Diseases,” in :Basic&Clinical Immunology, Sixth Edition, Stites, D.P. et al. (eds.) Norwalk, CT: Appleton & Lange, pp. 598-602 (1987).
Jonker, M. et al., “Successful Treatment of EAE in Rhesus Monkeys with MHC Class II Specific Monoclonal Antibodies,”J. Autoimmunity 1:399-414 (1988).
Kageshita, T. et al., “Differential Expression of Melanoma Associated Antigens in Acral Lentiginous Melanoma and in Nodular Melanoma Lesions,”Cancer Res. 51:1726-1732 (Mar. 15, 1991).
Kavanaugh, A.F. et al., “Treatment Of Refractory Rheumatoid Arthritis With An Anti-CD54 (Intercellular Adhesion Molecule-1, ICAM-1) Monoclonal Antibody,”Abstr. Proc. Amer. Coll. Rheumatology(1992).
Keizer, G.D. et al., “Biochemical and functional characteristics of the human leukocyte membrane antigen family LFA-1, Mo-1 and p150,95, ”Eur. J. Immunol. 15: 1142-1147 (1985).
Kishimoto, T.K. et al., “The Leukocyte Intgrins,”Adv. Immunol. 46:149-182 (1989).
Kohl, S. et al., “Defective Natural Killer Cytotoxicity And Polymorphonuclear Leukocyte Antibody-Dependent Cellular Cytotox
Dustin Michael L.
Marlin Steven D.
Rothlein Robert
Springer Timothy A.
Dana Farber Cancer Institute
Gambel Phillip
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Functional derivatives of ICAM-1 with altered ability to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functional derivatives of ICAM-1 with altered ability to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functional derivatives of ICAM-1 with altered ability to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772773